1. Home
  2. DAKT vs DRUG Comparison

DAKT vs DRUG Comparison

Compare DAKT & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Daktronics Inc.

DAKT

Daktronics Inc.

HOLD

Current Price

$20.13

Market Cap

872.1M

Sector

Industrials

ML Signal

HOLD

Logo Bright Minds Biosciences Inc.

DRUG

Bright Minds Biosciences Inc.

HOLD

Current Price

$71.00

Market Cap

707.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DAKT
DRUG
Founded
1968
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Office Equipment/Supplies/Services
Pharmaceuticals and Biotechnology
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
872.1M
707.1M
IPO Year
1996
2020

Fundamental Metrics

Financial Performance
Metric
DAKT
DRUG
Price
$20.13
$71.00
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$124.00
AVG Volume (30 Days)
602.4K
82.6K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.75
N/A
Revenue
$608,932,000.00
N/A
Revenue This Year
$13.76
N/A
Revenue Next Year
$7.35
N/A
P/E Ratio
$28.07
N/A
Revenue Growth
6.89
N/A
52 Week Low
$10.95
$23.18
52 Week High
$28.27
$123.75

Technical Indicators

Market Signals
Indicator
DAKT
DRUG
Relative Strength Index (RSI) 30.28 35.56
Support Level $18.53 $49.47
Resistance Level $20.50 $91.00
Average True Range (ATR) 1.12 4.55
MACD -0.75 -1.24
Stochastic Oscillator 0.59 9.05

Price Performance

Historical Comparison
DAKT
DRUG

About DAKT Daktronics Inc.

Daktronics Inc designs and manufactures electronic scoreboards, programmable display systems, and large-screen video displays for sporting, commercial, and transportation applications. It is engaged in a full range of activities: marketing and sales, engineering and product design and development, manufacturing, technical contracting, professional services, and customer service and support. The company offers a complete line of products, from small scoreboards and electronic displays to large multimillion-dollar video display systems as well as related control, timing, and sound systems. The company has five reportable segments: Commercial, Live Events, High School Park and Recreation, Transportation, and International. The company makes the majority of its revenue from Live events.

About DRUG Bright Minds Biosciences Inc.

Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

Share on Social Networks: